Sirolimus albumin bound

Drug Profile

Sirolimus albumin bound

Alternative Names: ABI-009; Nab-rapamycin; Nab-sirolimus

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Abraxis BioScience
  • Developer AADi; Celgene Corporation
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Perivascular epithelioid cell tumours
  • Phase I/II Bladder cancer
  • Phase I Pulmonary arterial hypertension
  • No development reported Solid tumours

Most Recent Events

  • 08 May 2017 Aadi Bioscience plans a phase I trial for Pulmonary arterial hypertension
  • 08 May 2017 Aadi Bioscience plans a phase II trial for Bladder cancer in
  • 01 Apr 2017 Phase-I clinical trials in Pulmonary arterial hypertension in USA (Parenteral) (NCT02587325)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top